STOCK TITAN

If You Invested in Oramed Pharmaceuticals Inc. (ORMP)

Healthcare · Biotechnology · NASDAQ
Looking for the current price? See the ORMP quote & overview
$1,000 invested 1 Year Ago
$1,384
+38.4% price return
+48.4% with dividends reinvested
Bought on Nov 21, 2025 at $2.58 split-adjusted
$1,000 invested 5 Years Ago
$188
-81.2% price return -28.4% CAGR
-79.8% with dividends reinvested
Bought on Nov 22, 2021 at $18.95 split-adjusted

What $1,000 or $10,000 in ORMP Would Be Worth Now

Real historical value by amount invested and how long ago
If you invested 1 year ago 5 years ago 10 years ago Since Nov 23, 2015
$1,000 $1,384 +38% $188 -81% $571 -43% $446 -55%
$10,000 $13,837 +38% $1,884 -81% $5,712 -43% $4,457 -55%

Based on real historical closing prices adjusted for stock splits, without dividends, through 2026-11-20. Figures with dividends reinvest each cash dividend at the previous close less the dividend, before taxes. Past performance does not guarantee future results.

Custom Calculation

Choose your own date and amount for ORMP

$1,000 Investment Over Time

ORMP vs S&P 500

Year-by-Year Returns

ORMP annual performance
Year Start Price End Price Annual Return Cumulative
2015Nov 23 to Dec 31 $8.01 $8.55 +6.7% +6.7%
2016 $8.55 $6.12 -28.4% -23.6%
2017 $6.12 $9.00 +47.1% +12.4%
2018 $9.00 $3.00 -66.7% -62.5%
2019 $3.00 $5.15 +71.7% -35.7%
2020 $5.15 $4.24 -17.7% -47.1%
2021 $4.24 $14.28 +236.8% +78.3%
2022 $14.28 $12.03 -15.8% +50.2%
2023 $12.03 $2.31 -80.8% -71.2%
2024 $2.31 $2.42 +4.8% -69.8%
2025 $2.42 $2.85 +17.8% -64.4%
2026Dec 31, 2025 to Nov 20 $2.85 $3.57 +25.3% -55.4%

About Oramed Pharmaceuticals Inc.

Healthcare · NASDAQ

Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) is a clinical-stage pharmaceutical company in the pharmaceutical preparation manufacturing industry that focuses on oral delivery solutions for drugs currently delivered via injection. The company describes itself as a platform technology pioneer in this field, built around its proprietary Protein Oral Delivery (POD™) technology, which is designed to protect drug integrity and increase absorption when administered orally.

According to multiple company disclosures, Oramed’s POD™ platform underpins its work on oral formulations of injectable therapies, including a refined oral insulin program. The company has reported extensive research and development efforts to transform injectable therapies into oral medications, and has developed oral dosage forms intended to withstand the harsh environment of the stomach and deliver active biological agents such as insulin.

Business focus and technology platform

Oramed’s core business is the research and development of oral drug delivery platforms. Its POD™ technology is repeatedly described in press releases and SEC filings as a novel protein oral delivery approach that aims to maintain drug stability and improve absorption in the gastrointestinal tract. This platform is used to support the company’s oral insulin program and other potential POD™-based oral drug delivery technologies.

The company has highlighted a refined oral insulin program based on analysis of prior Phase 2 and Phase 3 clinical data. In communications to shareholders, Oramed has discussed identifying high-responder subgroups in its clinical data and designing a U.S.-based trial to further evaluate its oral insulin formulation. These activities reflect its characterization as a clinical-stage pharmaceutical company focused on advancing oral insulin and related POD™-based candidates.

Strategic transactions and investment activities

Beyond internal R&D, Oramed has developed what it calls a diversified active investment portfolio across the biomedical landscape. Company press releases and shareholder letters describe structured investments in other healthcare and biotech businesses, including Scilex Holding Company, Alpha Tau Medical Ltd., BioXcel Therapeutics Inc., Pelthos Therapeutics Inc., and other earlier-stage biotech and real estate-related positions. These investments are presented as part of a broader strategy to deploy capital in opportunities that the company believes complement its core competencies.

In relation to Scilex, Oramed has entered into a senior secured promissory note, received repayments, and negotiated royalty interests on certain Scilex products. It has also entered into warrant and option agreements regarding Scilex equity. With Alpha Tau Medical, Oramed has entered into a strategic collaboration and service agreement, providing investor and shareholder outreach, business strategic guidance, and capital markets expertise, alongside a significant equity investment and governance role through board representation. These activities illustrate how Oramed combines its drug delivery platform with capital markets and business development capabilities.

Joint ventures and platform spin-outs

Oramed has announced and explored joint venture structures to further develop and commercialize its POD™ technology. In February 2025, the company disclosed definitive agreements to spin off its POD™ technology and oral insulin assets into a new joint venture, OraTech Pharmaceuticals Inc., with Hefei Tianhui Biotech Co., Ltd. (HTIT). Under those agreements, OraTech was expected to hold global marketing rights to Oramed’s POD™ oral protein delivery technology, receive capital contributions from Oramed and HTIT, and pursue Phase 3 trials and regulatory registrations for oral insulin in multiple territories.

Subsequent disclosures, however, indicate that this joint venture did not close as originally planned. In an October 2025 SEC filing, Oramed reported terminating the joint venture agreement and related supplemental agreement with HTIT after HTIT was unable to satisfy closing conditions. In later shareholder communications, Oramed stated that it planned to continue its oral insulin development program independently. These developments show how the company has adjusted its approach to partnering while maintaining its focus on oral insulin.

Strategic evolution and medical robotics exposure

In January 2026, Oramed announced binding agreements for a strategic transaction with Lifeward Ltd. (formerly ReWalk Robotics). Under this transaction, Oramed agreed to transfer its proprietary POD™ technology to Lifeward, while Oramed is expected to obtain a 49.9% beneficial ownership interest in Lifeward upon satisfaction of specified conditions. Oramed also agreed to invest in Lifeward’s senior secured convertible notes with associated warrant coverage, and to manage an anticipated clinical trial under a clinical trial management agreement.

Through this transaction, Oramed describes itself as combining continued exposure to oral drug delivery innovation with participation in a revenue-generating medical robotics company. Lifeward designs, develops, and commercializes technologies such as the FDA-approved ReWalk® Personal Exoskeleton and AlterG® Anti-Gravity Systems, and Oramed has highlighted the revenue generated by these product lines in recent periods. Oramed has also disclosed that it will receive a percentage of net sales from the ReWalk franchise for a specified period. This structure positions Oramed as both a technology contributor and a significant shareholder in Lifeward.

Capital allocation, shareholder actions, and corporate governance

Oramed’s public communications emphasize its approach to capital allocation and shareholder returns. The company has discussed a stock repurchase program, cash dividends, and the potential distribution of equity in affiliated entities (such as OraTech, when that transaction was contemplated) to its shareholders. In January 2026, Oramed announced a cash dividend payment funded with surplus capital, following returns from its Scilex investment. In November 2025, the Board of Directors adopted a Rights Agreement and declared a dividend of common stock purchase rights designed, as described in the company’s press release and related SEC filing, to address potential hostile takeover scenarios and to support equal treatment of stockholders in such events.

SEC filings show that Oramed’s common stock, par value $0.012 per share, is registered under Section 12(b) of the Securities Exchange Act of 1934 and trades under the symbol ORMP on The Nasdaq Capital Market and on the Tel Aviv Stock Exchange. The company is incorporated in Delaware. Its filings also describe corporate actions such as amendments to its stock incentive plan and the outcomes of annual stockholder meetings.

Geographic footprint

Oramed states in multiple press releases that it has offices in the United States and Israel. SEC filings list its principal executive offices in New York, New York. These disclosures indicate that the company operates across at least these two jurisdictions as it advances its clinical programs and investment activities.

Position within the pharmaceutical preparation manufacturing sector

Within the broader manufacturing sector, Oramed is classified under pharmaceutical preparation manufacturing. Its differentiation, based on its own descriptions, lies in its focus on oral delivery of drugs that are typically administered by injection, and in its use of the POD™ platform for protein and other biologic therapies. The company’s activities span clinical development, strategic partnerships, and financial investments in other biomedical and medical technology companies.

Market Cap
$155.2M
Current Price
$3.57
EPS (FY2025)
$1.50
Revenue (FY2025)
$2.0M
View full ORMP overview

Frequently Asked Questions

Oramed Pharmaceuticals Inc. investment returns

How much would $1,000 invested in Oramed Pharmaceuticals Inc. be worth today?

If you invested $1,000 in Oramed Pharmaceuticals Inc. (ORMP) 10 years ago on 2016-11-21, your investment would be worth $571 as of 2026-11-20, a -42.9% price return without dividends, growing at a compounded rate of -5.4% per year (CAGR).

Has Oramed Pharmaceuticals Inc. outperformed the S&P 500?

Over the past 10 years, ORMP returned -42.9% compared to +213.3% for the S&P 500, underperforming the benchmark by 256.2 percentage points.

What is Oramed Pharmaceuticals Inc.'s average annual return?

The compound annual growth rate (CAGR) of ORMP’s share price over the past 10 years is -5.4%, without dividends. Individual years vary a great deal, and ORMP’s best recent full year was 2021 (+236.8%) while the worst was 2023 (-80.8%).

For informational and educational purposes only, not investment advice.